ARIAD Pharmaceuticals, Inc. is a global oncology company focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines.

ARIAD Pharmaceuticals was acquired by Takeda Pharmaceutical on January 9, 2017

Type
Subsidiary
Parent Company
Takeda Pharmaceutical
HQ
Cambridge, US
Founded
1991
Website
ariad.com
ARIAD Pharmaceuticals was founded in 1991 and is headquartered in Cambridge, US
Report incorrect company information

ARIAD Pharmaceuticals Office Locations

ARIAD Pharmaceuticals has offices in Sacramento, Orlando, Philadelphia, Tucson and in 9 other locations
Cambridge, US (HQ)
40 Landsdowne Street
Show all (13)
Report incorrect company information

ARIAD Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

1991
ARIAD Pharmaceuticals is a subsidiary of Takeda Pharmaceutical

ARIAD Pharmaceuticals Financials

ARIAD Pharmaceuticals's revenue was reported to be $118.80 m in FY, 2015 which is a 12.7% increase from the previous period.
Annual
USDFY, 2013FY, 2014FY, 2015

Revenue

45.6 m105.4 m118.8 m

Revenue growth, %

131%13%

EBIT

(273.6 m)(160.2 m)(217.3 m)

EBIT margin, %

(600%)(152%)(183%)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Revenue

16.7 m11.8 m12.1 m14.7 m24 m29.2 m29.1 m35.6 m68.1 m46 m

Operating expense total

83 m61.4 m68.4 m61.8 m73.7 m87.8 m85.4 m83.5 m79.8 m71 m

EBIT

(66.2 m)(49.7 m)(56.3 m)(47.1 m)(49.7 m)(58.6 m)(56.4 m)(47.9 m)(11.7 m)(25 m)

EBIT margin, %

(396%)(421%)(465%)(321%)(207%)(200%)(194%)(134%)(17%)(54%)
Annual
USDFY, 2013FY, 2014FY, 2015

Cash

237.2 m352.7 m230.9 m

Accounts Receivable

1.3 m8.4 m15.7 m

Inventories

419 k

Current Assets

244.9 m385.6 m275.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Cash

284.4 m183 m310 m273.5 m304 m274 m282.2 m160.9 m273 m305 m

Accounts Receivable

7 m4.2 m5 m7.3 m11.3 m14.4 m15.5 m21.6 m14.1 m24 m

Inventories

577 k480 k925 k969 k704 k1.3 m1.5 m936 k903 k2.1 m

Current Assets

313.4 m199 m324.2 m289.4 m340.9 m301.1 m329.5 m209.2 m307.1 m351.2 m
Annual
USDFY, 2013FY, 2014FY, 2015

Net Income

(274.2 m)(162.6 m)(231.2 m)

Inventories

(413 k)(560 k)1.1 m

Accounts Payable

2.5 m(137 k)5.5 m

Cash From Operating Activities

(221.9 m)(57.8 m)(159.2 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q1, 2016Q2, 2016Q3, 2016

Net Income

(66.3 m)(49.8 m)(56.9 m)(50.1 m)(52.7 m)(53.8 m)56.1 m28.2 m

Inventories

(92 k)(1.1 m)(2.3 m)

Accounts Payable

(4 m)(6.8 m)(5.8 m)

Cash From Operating Activities

(65.1 m)(97.7 m)(121.4 m)
Show all financial metrics
Report incorrect company information